JP2022541761A5 - - Google Patents

Info

Publication number
JP2022541761A5
JP2022541761A5 JP2022502074A JP2022502074A JP2022541761A5 JP 2022541761 A5 JP2022541761 A5 JP 2022541761A5 JP 2022502074 A JP2022502074 A JP 2022502074A JP 2022502074 A JP2022502074 A JP 2022502074A JP 2022541761 A5 JP2022541761 A5 JP 2022541761A5
Authority
JP
Japan
Prior art keywords
protein
target protein
constituent polypeptide
fused
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502074A
Other languages
English (en)
Japanese (ja)
Other versions
JP7772687B2 (ja
JP2022541761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/056657 external-priority patent/WO2021009692A1/en
Publication of JP2022541761A publication Critical patent/JP2022541761A/ja
Publication of JP2022541761A5 publication Critical patent/JP2022541761A5/ja
Application granted granted Critical
Publication of JP7772687B2 publication Critical patent/JP7772687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502074A 2019-07-15 2020-07-15 タンパク質二量体化の三分子システム及び使用方法 Active JP7772687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874025P 2019-07-15 2019-07-15
US62/874,025 2019-07-15
PCT/IB2020/056657 WO2021009692A1 (en) 2019-07-15 2020-07-15 Tripartite systems for protein dimerization and methods of use

Publications (3)

Publication Number Publication Date
JP2022541761A JP2022541761A (ja) 2022-09-27
JP2022541761A5 true JP2022541761A5 (OSRAM) 2023-07-18
JP7772687B2 JP7772687B2 (ja) 2025-11-18

Family

ID=71895034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502074A Active JP7772687B2 (ja) 2019-07-15 2020-07-15 タンパク質二量体化の三分子システム及び使用方法

Country Status (5)

Country Link
US (1) US20220380801A1 (OSRAM)
EP (1) EP3999091A1 (OSRAM)
JP (1) JP7772687B2 (OSRAM)
CN (1) CN114127304B (OSRAM)
WO (1) WO2021009692A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3228137A1 (en) * 2021-08-09 2023-02-16 Harbour Biomed (Shanghai) Co., Ltd Cldn18.2-targeting antibody, bispecific antibody and use thereof
US20240228610A9 (en) * 2022-10-10 2024-07-11 Medimmune, Llc Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.2
WO2024261323A1 (en) 2023-06-23 2024-12-26 Astrazeneca Ab Molecular switches
CN116925190B (zh) * 2023-07-27 2026-03-24 浙江大学 一种靶向抑制DEF-p65复合物的多肽、多肽药物及其应用
CN117299070B (zh) * 2023-10-11 2025-09-12 安徽工业大学 一种Ca/Mg矿物凝胶的制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20040040047A1 (en) * 1998-03-30 2004-02-26 Spencer David M. Regulated apoptosis using chemically induced dimerization of apoptosis factors
JP2002534084A (ja) 1999-01-08 2002-10-15 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの修飾形
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
CA2796010C (en) 2010-04-13 2020-05-12 Medimmune, Llc Trail r2-specific multimeric scaffolds
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
US9738629B2 (en) * 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
HK1258313A1 (zh) * 2015-10-23 2019-11-08 Fred Hutchinson Cancer Center 建立化学诱导的二聚化蛋白体系以调节细胞事件的方法
CN108239656A (zh) * 2016-12-27 2018-07-03 天津天锐生物科技有限公司 一种小分子药物控制的蛋白功能开关系统
US11939379B2 (en) * 2017-05-19 2024-03-26 The Regents Of The University Of California Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法

Similar Documents

Publication Publication Date Title
KR102944460B1 (ko) Cldn18.2 및 cd3에 대한 항체 작제물
CN109476734B (zh) Cd70和cd3的抗体构建体
JP7011574B2 (ja) Ｆｌｔ３及びｃｄ３に対する抗体構築物
CN107922495B (zh) 结合egfrviii和cd3的双特异性抗体构建体
CA2454361C (en) Humanized antibodies
BR112021006558A2 (pt) proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
CN119371549A (zh) 结合dll3和cd3的双特异性抗体构建体
JP2022513383A (ja) 二重特異性抗体及びその作製方法と使用
BR112020011627A2 (pt) processo de fabricação contínuo para produtos de anticorpos biespecíficos
CN116964102A (zh) 四价fzd和wnt共受体结合抗体分子及其用途
CN115160433B (zh) 人源化hbv b和c基因型前s1蛋白抗体及其应用
JP2023178502A (ja) 抗ｃｄ３８及び抗ｃｄ１３８キメラ抗原受容体を含むｔ細胞、及びその用途
CN117164712B (zh) 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
CN110494163A (zh) 凝血因子viii模拟蛋白及其用途
CN112789058A (zh) 双特异性抗体构建体的下游加工
CN117279947A (zh) 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
TWI910636B (zh) 特異性結合cll1的抗體及其製法和應用
CN110885377A (zh) 抗cd47/vegf双特异性抗体及其应用
CN107880131A (zh) 一种抗IL‑13Rα2和CD3双特异抗体及其应用
CN116496400A (zh) 抗c-Met和抗MSLN抗体、其双嵌合抗原受体及其应用
WO2024193669A1 (zh) 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用
WO2023125813A1 (zh) 抗间皮素纳米抗体嵌合抗原受体及其应用
TWI904917B (zh) Ｔａｃｉ結合分子
WO2026016967A1 (zh) 一种融合蛋白及其用途
TW202615467A (zh) 特異性結合ｃｌｌ１的抗體及其製法和應用